Zoek een klinische studie of trial
Andere zoekoptie(s)
37 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Gefinancierd door een IRDiRC-lid = 
; Member of a ERN = 
Nationale klinische studie(s)
BELGIË
VLAAMS BRABANT
LEUVEN
A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - BE
UZ Leuven - Campus Gasthuisberg
General medical oncology/Algemene Medische Oncologie
DUITSLAND
Baden-Württemberg
HEIDELBERG
An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with locally advanced or metastatic Neoplasia
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
CHANGE2: A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck - DE
Institution: Information not provided - DE
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
IMPORTANCE : Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma
Institution: Information not provided - DE
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
CheckRad-CD8: First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration
Institution: Information not provided - DE
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - DE
Institution: Information not provided - DE
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
PROCLAIM-CX-2009: A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors -DE-
Institution: Information not provided - DE
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
ARTISTRY-2: A Phase 1/2 study of ALKS 4230 administered subcutaneously as monotherapy and in combination with Pembrolizumab in subjects with advanced solid tumors - DE
Institution: Information not provided - DE
DUITSLAND
Nordrhein-Westfalen
ESSEN
OPTIM: A Randomized Phase II Study on the OPTimization of IMmunotherapy in Squamous Carcinoma of the Head and Neck
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Innere Medizin (Tumorforschung)
FRANKRIJK
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - FR
Institution: Information not provided - FR
FRANKRIJK
AUVERGNE-RHONE-ALPES
LYON
PIK-ORL: A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a Phosphoinositide 3-kinase (PI3K) Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy.
CLCC Léon Bérard
Centre Léon Bérard
FRANKRIJK
BOURGOGNE-FRANCHE-COMTE
BESANÇON
OMET (GORTEC 2014-04) : Randomized Phase II Trial Comparing Chemotherapy Combined With Stereotactic Radiotherapy and Stereotactic Radiotherapy Alone, for Treatment of Oligometastases in Squamous Cell Cancers of the Upper Aerodigestive Tract
CHRU de Besançon - Hôpital Jean Minjoz
Service de Radiothérapie - Oncologie
FRANKRIJK
ILE-DE-FRANCE
PARIS
DEBIO 1143-201 : A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck - FR
CLCC Institut Curie
Département d'Oncologie médicale - Cancers ORL
FRANKRIJK
ILE-DE-FRANCE
SAINT-MANDÉ
SANTAL (GORTEC 2016-02) : A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors
Hôpital d'Instruction des Armées Bégin
Service d'oncologie
ITALIË
PIEMONTE
CUNEO
The CONFRONT Phase I - II Trial: ACtivatiON oF Immune RespONse in paTients With R-M Head and Neck Cancer. Multimodality Immunotherapy With Avelumab, Short Course Radiotherapy and Cyclophosphamide in Head and Neck Cancer
A. O. Santa Croce e Carle - Ospedale S.Croce
S.C. Oncologia Medica
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
KEYNOTE-669/ECHO-304: A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
AIM-HN/SEQ-HN: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (Phase 2) - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma - AT
Institution: Information not provided - AT
SPANJE
Andalucía
MARBELLA
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Costa del Sol
Servicio de Oncología
SPANJE
Andalucía
MÁLAGA
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Universitario Virgen de la Victoria
Unidad de Oncología Médica
SPANJE
Aragón
ZARAGOZA
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Universitario Miguel Servet
Servicio de Oncología Médica
SPANJE
Cataluña
BARCELONA
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Clínic de Barcelona
Servicio de Oncología Médica
SPANJE
Cataluña
L'HOSPITALET DE LLOBREGAT
BioLateTox: Identification of tissue biomarkers related to late toxicity in Head and Neck Cancer Patients treated with chemoradiotherapy or bioradiotherapy (Phase IV) - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Oncología Médica
SPANJE
Cataluña
L'HOSPITALET DE LLOBREGAT
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Oncología Médica
SPANJE
Comunidad Valenciana
VALENCIA
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Oncología Médica
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
ARTISTRY-2: A Phase 1/2 study of ALKS 4230 administered subcutaneously as monotherapy and in combination with Pembrolizumab in subjects with advanced solid tumors - ES
Institution: Information not provided - ES
SPANJE
Madrid
MADRID
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
SPANJE
Madrid
MADRID
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Universitario HM Sanchinarro
Servicio de Oncología Médica
SPANJE
Madrid
MADRID
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Universitario La Paz
Servicio de Oncología Médica
SPANJE
Navarra
PAMPLONA
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Complejo Hospitalario de Navarra
Servicio de Oncología médica
VERENIGD KONINKRIJK
Antrim and Newtownabbey
BELFAST
A Cancer Research UK (CR-UK) Phase I Trial of LY3143921 a Cdc7 Inhibitor in Adult Patients With Advanced Solid Tumours
Belfast City Hospital
The Northern Ireland Cancer Centre
ZWITSERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
KEYNOTE-669/ECHO-304: A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - GB
Institution: Information not provided - CH
BELGIË
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
Multinationale klinische studie(s)
NOORWEGEN
Østlandet
ADDRESS: NOT PROVIDED - NO
An open-label, single arm, multi-centre, Phase II study to evaluate the safety and efficacy of PC-A11 with superficial and interstitial laser light application in patients with recurrent head and neck squamous cell carcinoma unsuitable for surgery and radiotherapy
Institution: Information not provided - NO
ZWITSERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH